Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anette Sommer

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
British Journal of Cancer|December 8, 2021
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansineVincent Chen, Shigeki Umemura, Yumin Han, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|August 11, 2012
Tissue remodeling and nonendometrium-like menstrual cycling are hallmarks of peritoneal endometriosis lesionsFlorian Sohler, Anette Sommer, David L Wachter, et al.
Cancers|November 25, 2020
IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic MalignanciesDennis Kirchhoff, Beatrix Stelte-Ludwig, Hans-Georg Lerchen, et al.
Journal of Alzheimer'S Disease : JAD|October 17, 2014
Alzheimer amyloid peptide aβ42 regulates gene expression of transcription and growth factorsChristian Barucker, Anette Sommer, Georg Beckmann, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 2019
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344Katrine Wickstroem, Urs B Hagemann, Alexander Kristian, et al.
Cancer Research|August 21, 2016
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid TumorsAnette Sommer, Charlotte Kopitz, Christoph A Schatz, et al.
Bioconjugate Chemistry|June 6, 2022
A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer TherapyNiels Böhnke, Markus Berger, Nils Griebenow, et al.
Cell Reports. Medicine|January 14, 2022
TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancerRichard E Beatson, Ana C Parente-Pereira, Leena Halim, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
British Journal of Cancer|December 8, 2021
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansineVincent Chen, Shigeki Umemura, Yumin Han, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|August 11, 2012
Tissue remodeling and nonendometrium-like menstrual cycling are hallmarks of peritoneal endometriosis lesionsFlorian Sohler, Anette Sommer, David L Wachter, et al.
Cancers|November 25, 2020
IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic MalignanciesDennis Kirchhoff, Beatrix Stelte-Ludwig, Hans-Georg Lerchen, et al.
Journal of Alzheimer'S Disease : JAD|October 17, 2014
Alzheimer amyloid peptide aβ42 regulates gene expression of transcription and growth factorsChristian Barucker, Anette Sommer, Georg Beckmann, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 2019
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344Katrine Wickstroem, Urs B Hagemann, Alexander Kristian, et al.
Cancer Research|August 21, 2016
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid TumorsAnette Sommer, Charlotte Kopitz, Christoph A Schatz, et al.
Bioconjugate Chemistry|June 6, 2022
A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer TherapyNiels Böhnke, Markus Berger, Nils Griebenow, et al.
Cell Reports. Medicine|January 14, 2022
TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancerRichard E Beatson, Ana C Parente-Pereira, Leena Halim, et al.
Pageof 4